These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19136678)

  • 1. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
    Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
    Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
    Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
    J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
    Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
    Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
    Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
    J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
    Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
    Gianotti N; Tambussi G; Boeri E; Lazzarin A
    J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
    Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
    J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
    Calazans A; Brindeiro R; Brindeiro P; Verli H; Arruda MB; Gonzalez LM; Guimaraes JA; Diaz RS; Antunes OA; Tanuri A
    J Infect Dis; 2005 Jun; 191(11):1961-70. PubMed ID: 15871131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.